
Recursion Pharmaceuticals (NASDAQ:RXRX) brought in sales totaling $2.53 million during Q4 according to data provided by Benzinga Pro. However, earnings decreased 36.91%, resulting in a loss of $64.93 million. In Q3, Recursion Pharmaceuticals brought in $2.53 million in sales but lost $47.43 million in earnings.